You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEliglustat
Accession NumberDB09039
TypeSmall Molecule
GroupsApproved
DescriptionEliglustat, marketed by Genzyme as CERDELGA, is a glucosylceramide synthase inhibitor indicated for the long-term treatment of type 1 Gaucher disease. Patients selected for treatment with Eliglustat undergo an FDA approved genotype test to establish if they are CYP2D6 EM (extensive metabolizers), IM (intermediate metabolizers), or PM (poor metabolizers), as the results of this test dictate the dosage of Eliglustat recommended. Eliglustat was approved for use by the FDA in August 2014.
Structure
Thumb
Synonyms
N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide
External Identifiers
  • A16AX10
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cerdelgacapsule84 mg/1oralGenzyme Corporation2014-09-03Not applicableUs
CerdelgaCapsule, hard84 mgOral useGenzyme Europe Bv2015-01-19Not applicableEu
CerdelgaCapsule, hard84 mgOral useGenzyme Europe Bv2015-01-19Not applicableEu
CerdelgaCapsule, hard84 mgOral useGenzyme Europe Bv2015-01-19Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
eliglustat tartrate
ThumbNot applicableDBSALT001106
Categories
UNIIDR40J4WA67
CAS number491833-29-5
WeightAverage: 404.551
Monoisotopic: 404.267507647
Chemical FormulaC23H36N2O4
InChI KeyFJZZPCZKBUKGGU-AUSIDOKSSA-N
InChI
InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1
IUPAC Name
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanimidic acid
SMILES
[H][C@](CN1CCCC1)(N=C(O)CCCCCCC)[C@]([H])(O)C1=CC2=C(OCCO2)C=C1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationEliglustat is indicated for the long-term treatment of type 1 Gaucher disease in patients who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) in treatment-naive and treatment-experienced adult patients.
PharmacodynamicsAccording to pharmacokinetic and pharmacodynamic modelling, plasma concentrations of 500ng/mL of eliglustat are predicted to increase mean concentration in the PR, QRS, and QTcF intervals of 22, 7, and 13 msec, respectively. (Taken from Cerdelga prescribing information).
Mechanism of actionEliglustat is a glucosylceramide synthase (IC50 = 10 ng/mL) specific inhibitor that acts as a substrate inhibitor of glucosylceramide.
Related Articles
AbsorptionIn CYP2D6 EMs (extensive metabolizers), median time to reach maximum plasma concentrations (tmax) occurs at 1.5 to 2 hours following multiple doses of eliglustat 84 mg twice daily.
Volume of distribution

835 L in CYP2D6 EMs (extensive metabolizers).

Protein binding76 to 83%.
Metabolism

Extensively metabolized, primarily by CYP2D6 and less so by CYP3A4. No active metabolites have been identified.

Route of eliminationUrine (41.8%) and feces (51.4%), mainly as metabolites after oral administration.
Half life6.5 hours in EM (extensive metabolizers) and 8.9 hours in PM (poor metabolizers).
Clearance

88 L/h (8.8%) in CYP2D6 EM (extensive metabolizers).

ToxicityIn rats, eliglustat increased pre-implantation loss at 30 and 100 mg/kg/day. In male mature rats, eliglustat showed reversible adverse affects on sperm morphology, germ cell necrosis, and sloughed cells in the epididymis.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral84 mg/1
Capsule, hardOral use84 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6916802 No2002-04-292022-04-29Us
US7196205 No2002-04-292022-04-29Us
US7615573 No2002-04-292022-04-29Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.038 mg/mLALOGPS
logP3.79ALOGPS
logP1.46ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)5.21ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.52 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity114.28 m3·mol-1ChemAxon
Polarizability46 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Poole RM: Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36. doi: 10.1007/s40265-014-0296-3. [PubMed:25239269 ]
External Links
ATC CodesA16AX10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (376 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Eliglustat.
AbirateroneThe metabolism of Eliglustat can be decreased when combined with Abiraterone.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Eliglustat.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Eliglustat.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Eliglustat.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Eliglustat.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Eliglustat.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Eliglustat.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Eliglustat.
AmantadineAmantadine may increase the QTc-prolonging activities of Eliglustat.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Eliglustat.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Eliglustat.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Eliglustat.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Eliglustat.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Eliglustat.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Eliglustat.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Eliglustat.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Eliglustat.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Eliglustat.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Eliglustat.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Eliglustat.
ApomorphineApomorphine may increase the QTc-prolonging activities of Eliglustat.
AprepitantThe serum concentration of Eliglustat can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Eliglustat.
ArformoterolArformoterol may increase the QTc-prolonging activities of Eliglustat.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Eliglustat.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Eliglustat.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Eliglustat.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Eliglustat.
ArtemetherArtemether may increase the QTc-prolonging activities of Eliglustat.
AsenapineAsenapine may increase the QTc-prolonging activities of Eliglustat.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Eliglustat.
AtazanavirThe serum concentration of Eliglustat can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Eliglustat can be decreased when combined with Atomoxetine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Eliglustat.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Eliglustat.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Eliglustat.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Eliglustat.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Eliglustat.
BepridilThe metabolism of Bepridil can be decreased when combined with Eliglustat.
BetaxololThe metabolism of Eliglustat can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Eliglustat can be decreased when it is combined with Bexarotene.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Eliglustat.
BoceprevirThe serum concentration of Eliglustat can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Eliglustat can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Eliglustat can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Eliglustat.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Eliglustat.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Eliglustat.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Eliglustat.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Eliglustat.
BupropionThe serum concentration of Eliglustat can be increased when it is combined with Bupropion.
BupropionThe metabolism of Bupropion can be decreased when combined with Eliglustat.
BuserelinBuserelin may increase the QTc-prolonging activities of Eliglustat.
BuspironeThe metabolism of Buspirone can be decreased when combined with Eliglustat.
CaffeineThe metabolism of Caffeine can be decreased when combined with Eliglustat.
CaptoprilThe metabolism of Captopril can be decreased when combined with Eliglustat.
CarbamazepineThe serum concentration of Eliglustat can be decreased when it is combined with Carbamazepine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Eliglustat.
CarteololThe metabolism of Carteolol can be decreased when combined with Eliglustat.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Eliglustat.
CelecoxibThe metabolism of Eliglustat can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Eliglustat.
CeritinibCeritinib may increase the QTc-prolonging activities of Eliglustat.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Eliglustat.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Eliglustat.
ChloroquineChloroquine may increase the QTc-prolonging activities of Eliglustat.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Eliglustat.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Eliglustat.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Eliglustat.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Eliglustat.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Eliglustat.
CholecalciferolThe metabolism of Eliglustat can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Eliglustat.
CimetidineThe metabolism of Eliglustat can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Eliglustat can be increased when it is combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Eliglustat.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Eliglustat.
CisaprideCisapride may increase the QTc-prolonging activities of Eliglustat.
CitalopramCitalopram may increase the QTc-prolonging activities of Eliglustat.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Eliglustat.
ClemastineThe metabolism of Eliglustat can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Eliglustat.
ClobazamThe metabolism of Eliglustat can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Eliglustat can be decreased when combined with Clomipramine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Eliglustat.
ClotrimazoleThe metabolism of Eliglustat can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Eliglustat.
ClozapineThe metabolism of Clozapine can be decreased when combined with Eliglustat.
CobicistatThe serum concentration of Eliglustat can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Eliglustat can be increased when it is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Eliglustat.
ConivaptanThe serum concentration of Eliglustat can be increased when it is combined with Conivaptan.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Eliglustat.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Eliglustat.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Eliglustat.
CyclosporineThe metabolism of Eliglustat can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Eliglustat can be decreased when it is combined with Dabrafenib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Eliglustat.
DarifenacinThe metabolism of Eliglustat can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Eliglustat can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Eliglustat.
DasatinibThe serum concentration of Eliglustat can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Eliglustat.
DeferasiroxThe serum concentration of Eliglustat can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Eliglustat.
DelavirdineThe metabolism of Eliglustat can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Eliglustat.
DesipramineThe metabolism of Eliglustat can be decreased when combined with Desipramine.
DexamethasoneThe serum concentration of Eliglustat can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Eliglustat.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Eliglustat.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Eliglustat.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Eliglustat.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Eliglustat.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Eliglustat.
DihydroergotamineThe metabolism of Eliglustat can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Eliglustat can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Eliglustat can be decreased when combined with Diphenhydramine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Eliglustat.
DofetilideDofetilide may increase the QTc-prolonging activities of Eliglustat.
DolasetronDolasetron may increase the QTc-prolonging activities of Eliglustat.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Eliglustat.
DomperidoneDomperidone may increase the QTc-prolonging activities of Eliglustat.
DonepezilThe metabolism of Donepezil can be decreased when combined with Eliglustat.
DopamineThe metabolism of Dopamine can be decreased when combined with Eliglustat.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Eliglustat.
DoxepinDoxepin may increase the QTc-prolonging activities of Eliglustat.
DoxepinThe metabolism of Doxepin can be decreased when combined with Eliglustat.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Eliglustat.
DoxycyclineThe metabolism of Eliglustat can be decreased when combined with Doxycycline.
DronedaroneDronedarone may increase the QTc-prolonging activities of Eliglustat.
DroperidolDroperidol may increase the QTc-prolonging activities of Eliglustat.
DuloxetineThe metabolism of Eliglustat can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Eliglustat can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Eliglustat.
EncainideThe metabolism of Encainide can be decreased when combined with Eliglustat.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Eliglustat.
EnzalutamideThe serum concentration of Eliglustat can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Eliglustat.
EribulinEribulin may increase the QTc-prolonging activities of Eliglustat.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Eliglustat.
ErythromycinErythromycin may increase the QTc-prolonging activities of Eliglustat.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Eliglustat.
Eslicarbazepine acetateThe serum concentration of Eliglustat can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Eliglustat.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Eliglustat.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Eliglustat.
EtravirineThe serum concentration of Eliglustat can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Eliglustat.
FamotidineFamotidine may increase the QTc-prolonging activities of Eliglustat.
FelbamateFelbamate may increase the QTc-prolonging activities of Eliglustat.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Eliglustat.
FingolimodFingolimod may increase the QTc-prolonging activities of Eliglustat.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Eliglustat.
FlecainideFlecainide may increase the QTc-prolonging activities of Eliglustat.
FlecainideThe metabolism of Flecainide can be decreased when combined with Eliglustat.
FluconazoleThe metabolism of Eliglustat can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Eliglustat.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Eliglustat.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Eliglustat.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Eliglustat.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Eliglustat.
FluvoxamineThe metabolism of Eliglustat can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Eliglustat.
FormoterolThe metabolism of Formoterol can be decreased when combined with Eliglustat.
FosamprenavirThe metabolism of Eliglustat can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Eliglustat can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Eliglustat.
FosphenytoinThe serum concentration of Eliglustat can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Eliglustat can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Eliglustat.
GalantamineGalantamine may increase the QTc-prolonging activities of Eliglustat.
GalantamineThe metabolism of Galantamine can be decreased when combined with Eliglustat.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Eliglustat.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Eliglustat.
GoserelinGoserelin may increase the QTc-prolonging activities of Eliglustat.
GranisetronGranisetron may increase the QTc-prolonging activities of Eliglustat.
GranisetronThe metabolism of Granisetron can be decreased when combined with Eliglustat.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Eliglustat.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Eliglustat.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Eliglustat.
HalothaneThe metabolism of Halothane can be decreased when combined with Eliglustat.
HistrelinHistrelin may increase the QTc-prolonging activities of Eliglustat.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Eliglustat.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Eliglustat.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Eliglustat.
IbandronateIbandronate may increase the QTc-prolonging activities of Eliglustat.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Eliglustat.
IbutilideIbutilide may increase the QTc-prolonging activities of Eliglustat.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Eliglustat.
IdelalisibThe serum concentration of Eliglustat can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may increase the QTc-prolonging activities of Eliglustat.
ImatinibThe metabolism of Eliglustat can be decreased when combined with Imatinib.
ImipramineThe metabolism of Eliglustat can be decreased when combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Eliglustat.
IndapamideIndapamide may increase the QTc-prolonging activities of Eliglustat.
IndinavirThe metabolism of Eliglustat can be decreased when combined with Indinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Eliglustat.
IsavuconazoniumThe metabolism of Eliglustat can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Eliglustat.
IsoniazidThe metabolism of Eliglustat can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Eliglustat can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Eliglustat can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Eliglustat.
IvacaftorThe serum concentration of Eliglustat can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Eliglustat.
KetoconazoleThe metabolism of Eliglustat can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Eliglustat.
LapatinibLapatinib may increase the QTc-prolonging activities of Eliglustat.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Eliglustat.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Eliglustat.
LevodopaThe metabolism of Levodopa can be decreased when combined with Eliglustat.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Eliglustat.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Eliglustat.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Eliglustat.
LisurideThe metabolism of Lisuride can be decreased when combined with Eliglustat.
LithiumLithium may increase the QTc-prolonging activities of Eliglustat.
LomustineThe metabolism of Lomustine can be decreased when combined with Eliglustat.
LoperamideThe metabolism of Loperamide can be decreased when combined with Eliglustat.
LopinavirLopinavir may increase the QTc-prolonging activities of Eliglustat.
LoratadineThe metabolism of Loratadine can be decreased when combined with Eliglustat.
LorcaserinThe metabolism of Eliglustat can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Eliglustat can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Eliglustat can be increased when it is combined with Luliconazole.
LumefantrineLumefantrine may increase the QTc-prolonging activities of Eliglustat.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Eliglustat.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Eliglustat.
MefloquineMefloquine may increase the QTc-prolonging activities of Eliglustat.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Eliglustat.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Eliglustat.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Eliglustat.
MethadoneMethadone may increase the QTc-prolonging activities of Eliglustat.
MethadoneThe metabolism of Methadone can be decreased when combined with Eliglustat.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Eliglustat.
MethotrimeprazineThe serum concentration of Eliglustat can be increased when it is combined with Methotrimeprazine.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Eliglustat.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Eliglustat.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Eliglustat.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Eliglustat.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Eliglustat.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Eliglustat.
MetoprololThe metabolism of Eliglustat can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Eliglustat.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Eliglustat.
MianserinThe metabolism of Mianserin can be decreased when combined with Eliglustat.
MifepristoneMifepristone may increase the QTc-prolonging activities of Eliglustat.
MinaprineThe metabolism of Minaprine can be decreased when combined with Eliglustat.
MirabegronThe metabolism of Eliglustat can be decreased when combined with Mirabegron.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Eliglustat.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Eliglustat.
MitotaneThe serum concentration of Eliglustat can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Eliglustat.
ModafinilThe serum concentration of Eliglustat can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Eliglustat.
MorphineThe metabolism of Morphine can be decreased when combined with Eliglustat.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Eliglustat.
NafcillinThe serum concentration of Eliglustat can be decreased when it is combined with Nafcillin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Eliglustat.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Eliglustat.
NefazodoneThe serum concentration of Eliglustat can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Eliglustat.
NelfinavirThe serum concentration of Eliglustat can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Eliglustat can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Eliglustat.
NevirapineThe serum concentration of Eliglustat can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Eliglustat.
NicardipineThe metabolism of Eliglustat can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Eliglustat.
NicotineThe metabolism of Nicotine can be decreased when combined with Eliglustat.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Eliglustat.
NilotinibNilotinib may increase the QTc-prolonging activities of Eliglustat.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Eliglustat.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Eliglustat.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Eliglustat.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Eliglustat.
OctreotideOctreotide may increase the QTc-prolonging activities of Eliglustat.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Eliglustat.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Eliglustat.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Eliglustat.
OlaparibThe metabolism of Eliglustat can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Eliglustat.
OndansetronOndansetron may increase the QTc-prolonging activities of Eliglustat.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Eliglustat.
OsimertinibThe serum concentration of Eliglustat can be increased when it is combined with Osimertinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Eliglustat.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Eliglustat.
OxytocinOxytocin may increase the QTc-prolonging activities of Eliglustat.
PalbociclibThe serum concentration of Eliglustat can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Eliglustat.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Eliglustat.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Eliglustat.
ParoxetineThe serum concentration of Eliglustat can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Eliglustat.
PasireotidePasireotide may increase the QTc-prolonging activities of Eliglustat.
PazopanibPazopanib may increase the QTc-prolonging activities of Eliglustat.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Eliglustat.
Peginterferon alfa-2bThe serum concentration of Eliglustat can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Eliglustat.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Eliglustat.
PentobarbitalThe serum concentration of Eliglustat can be decreased when it is combined with Pentobarbital.
PerflutrenPerflutren may increase the QTc-prolonging activities of Eliglustat.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Eliglustat.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Eliglustat.
PethidineThe metabolism of Pethidine can be decreased when combined with Eliglustat.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Eliglustat.
PhenforminThe metabolism of Phenformin can be decreased when combined with Eliglustat.
PhenobarbitalThe serum concentration of Eliglustat can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Eliglustat can be decreased when it is combined with Phenytoin.
PimozidePimozide may increase the QTc-prolonging activities of Eliglustat.
PindololThe metabolism of Pindolol can be decreased when combined with Eliglustat.
PiperazineThe metabolism of Piperazine can be decreased when combined with Eliglustat.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Eliglustat.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Eliglustat.
PosaconazoleThe serum concentration of Eliglustat can be increased when it is combined with Posaconazole.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Eliglustat.
PrimidoneThe serum concentration of Eliglustat can be decreased when it is combined with Primidone.
ProcainamideProcainamide may increase the QTc-prolonging activities of Eliglustat.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Eliglustat.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Eliglustat.
PromazinePromazine may increase the QTc-prolonging activities of Eliglustat.
PromethazinePromethazine may increase the QTc-prolonging activities of Eliglustat.
PromethazineThe metabolism of Promethazine can be decreased when combined with Eliglustat.
PropafenonePropafenone may increase the QTc-prolonging activities of Eliglustat.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Eliglustat.
PropofolPropofol may increase the QTc-prolonging activities of Eliglustat.
PropofolThe metabolism of Propofol can be decreased when combined with Eliglustat.
PropranololThe metabolism of Propranolol can be decreased when combined with Eliglustat.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Eliglustat.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Eliglustat.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Eliglustat.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Eliglustat.
QuinidineQuinidine may increase the QTc-prolonging activities of Eliglustat.
QuinineQuinine may increase the QTc-prolonging activities of Eliglustat.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Eliglustat.
RanolazineThe metabolism of Eliglustat can be decreased when combined with Ranolazine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Eliglustat.
repinotanThe metabolism of repinotan can be decreased when combined with Eliglustat.
RifabutinThe serum concentration of Eliglustat can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Eliglustat can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Eliglustat can be decreased when it is combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Eliglustat.
RisperidoneRisperidone may increase the QTc-prolonging activities of Eliglustat.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Eliglustat.
RitonavirThe serum concentration of Eliglustat can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Eliglustat.
RolapitantThe metabolism of Eliglustat can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Eliglustat can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Eliglustat.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Eliglustat.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Eliglustat.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Eliglustat.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Eliglustat.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Eliglustat.
SertindoleThe metabolism of Sertindole can be decreased when combined with Eliglustat.
SertralineThe metabolism of Eliglustat can be decreased when combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Eliglustat.
SildenafilThe metabolism of Eliglustat can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Eliglustat can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Eliglustat can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Eliglustat.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Eliglustat.
SorafenibSorafenib may increase the QTc-prolonging activities of Eliglustat.
SotalolSotalol may increase the QTc-prolonging activities of Eliglustat.
SparteineThe metabolism of Sparteine can be decreased when combined with Eliglustat.
St. John's WortThe serum concentration of Eliglustat can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Eliglustat can be increased when it is combined with Stiripentol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Eliglustat.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Eliglustat.
SunitinibSunitinib may increase the QTc-prolonging activities of Eliglustat.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Eliglustat.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Eliglustat.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Eliglustat.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Eliglustat.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Eliglustat.
TelaprevirThe serum concentration of Eliglustat can be increased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Eliglustat.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Eliglustat.
TerbinafineThe serum concentration of Eliglustat can be increased when it is combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Eliglustat.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Eliglustat.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Eliglustat.
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Eliglustat.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Eliglustat.
ThioridazineThioridazine may increase the QTc-prolonging activities of Eliglustat.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Eliglustat.
TiclopidineThe metabolism of Eliglustat can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Eliglustat.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Eliglustat.
TipranavirThe serum concentration of Eliglustat can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Eliglustat.
TizanidineTizanidine may increase the QTc-prolonging activities of Eliglustat.
TocilizumabThe serum concentration of Eliglustat can be decreased when it is combined with Tocilizumab.
TolterodineTolterodine may increase the QTc-prolonging activities of Eliglustat.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Eliglustat.
ToremifeneToremifene may increase the QTc-prolonging activities of Eliglustat.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Eliglustat.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Eliglustat.
TranylcypromineThe metabolism of Eliglustat can be decreased when combined with Tranylcypromine.
TrazodoneTrazodone may increase the QTc-prolonging activities of Eliglustat.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Eliglustat.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Eliglustat.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Eliglustat.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Eliglustat.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Eliglustat.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Eliglustat.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Eliglustat.
VandetanibVandetanib may increase the QTc-prolonging activities of Eliglustat.
VardenafilVardenafil may increase the QTc-prolonging activities of Eliglustat.
VemurafenibVemurafenib may increase the QTc-prolonging activities of Eliglustat.
VenlafaxineThe metabolism of Eliglustat can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Eliglustat can be decreased when combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Eliglustat.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Eliglustat.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Eliglustat.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Eliglustat.
VoriconazoleThe serum concentration of Eliglustat can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Eliglustat.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Eliglustat.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Eliglustat.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Eliglustat.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Eliglustat.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Eliglustat.
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Eliglustat.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Ceramide glucosyltransferase activity
Specific Function:
Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a "flippase".
Gene Name:
UGCG
Uniprot ID:
Q16739
Molecular Weight:
44853.255 Da
References
  1. Poole RM: Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36. doi: 10.1007/s40265-014-0296-3. [PubMed:25239269 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Poole RM: Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36. doi: 10.1007/s40265-014-0296-3. [PubMed:25239269 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Poole RM: Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36. doi: 10.1007/s40265-014-0296-3. [PubMed:25239269 ]
Comments
comments powered by Disqus
Drug created on April 02, 2015 10:54 / Updated on September 28, 2016 02:27